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Abstract. Background: The standard of care for ST-
segment elevation myocardial infarction (STEMI) is
prompt coronary reperfusion with thrombolysis or per-
cutaneous coronary intervention. Women have higher
mortality rates than men following STEMI and fewer
women are considered eligible for reperfusion therapy.
We analyzed the impact of gender, and other factors, on
the outcome and treatment of STEMI in the TETAMI
trial and registry.
Methods: This exploratory analysis included 2741 pa-
tients from Treatment with Enoxaparin and Tirofiban
in Acute Myocardial Infarction (TETAMI) presenting
with STEMI within 24 hours of symptom onset. The pri-
mary composite end point was the combined incidence
of all-cause death, recurrent myocardial infarction, and
recurrent angina, at 30 days. Three multivariate anal-
yses were performed to determine predictors of not re-
ceiving reperfusion therapy, the composite end point,
or death.
Results: The triple end point occurred in 17.8% of
women versus 13.3% of men. Reperfusion therapy was
utilized in 38.2% of women versus 47.3% in men. How-
ever, age >75 years, delayed presentation, high sys-
tolic blood pressure (>100) and region (South Africa),
were significant, independent predictors of not receiv-
ing reperfusion therapy. Significant predictors of the
triple end point included not receiving reperfusion
therapy, age >60 years, and higher Killip class. Predic-
tors of death included age>60 years, low systolic blood
pressure, higher Killip class, high heart rate, delayed
presentation, and region (South Africa and South Amer-
ica).
Conclusion: Female gender was not an independent
predictor of outcome or underutilization of reperfusion
therapy. Factors more common in female STEMI pa-
tients (advanced age and delayed presentation) were
associated with not receiving reperfusion therapy and
adverse outcome. Increased awareness is needed to re-
duce delayed presentation after symptom onset, espe-
cially among women.
Abbreviated abstract. In this analysis of 2741 ST-
segment elevation myocardial infarction patients in the
TETAMI trial and registry, a trend was observed for
women being less likely to receive reperfusion therapy
and more likely to have an adverse outcome than men.
This was related to factors more common in female pa-
tients (advanced age and delayed presentation), and
showed that an increased awareness is needed to re-
duce delayed presentation after symptom onset, espe-
cially among women.
Key Words. ST-segment elevation myocardial
infarction, reperfusion therapy, gender
Introduction
Overwhelming evidence supports the use of reperfu-
sion therapy, either with thrombolytic drugs or per-
cutaneous coronary intervention, in patients with
ST-segment elevation myocardial infarction (STEMI)
who are admitted to hospital within 12 hours of
symptom onset [1,2]. Nevertheless, many patients
with STEMI do not receive reperfusion therapy [3,4].
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Reasons for withholding therapy include presenta-
tion after the 12-hour therapeutic window, advanced
age, gender, and geographic variations in manage-
ment practices [3–6]. The Treatment with Enoxa-
parin and Tirofiban in Acute Myocardial Infarction
(TETAMI) randomized trial evaluated different an-
tithrombotic regimens in STEMI patients who were
not eligible for reperfusion therapy, thus present-
ing a unique opportunity to analyze non-reperfused
patients [7,8]. The TETAMI registry included the
STEMI patients admitted to the same institutions
who received reperfusion therapy, as well as those
who neither received reperfusion therapy nor were
enrolled in the randomized trial [9]. The aim of
the present analysis was to analyze data from the
TETAMI study (trial and registry) to determine if,
and why, women are less likely to receive reperfu-
sion therapy and to compare outcomes after STEMI
in women with those in men.
Methods
Patient selection
The design and methods of the TETAMI random-
ized trial have been described previously in detail
[7,8]. Briefly, patients had to be 18 years of age
or older with acute STEMI. For inclusion, all pa-
tients were required to have ischemic symptoms of
at least 30 minutes duration within the previous 24
hours, accompanied by sustained ST-segment eleva-
tion of >0.2 mV in at least 2 precordial leads, or of
>0.1 mV in limb leads, or new left-bundle-branch
block or new Q wave plus elevated levels of creatinine
kinase-MB, creatinine kinase, or serum troponin. Ex-
clusion criteria included Killip class IV, cardiogenic
shock, planned revascularization within 48 hours,
contraindications to any of the study drugs, throm-
bocytopenia, current treatment with anticoagulants
or a glycoprotein IIb/IIIa receptor antagonist, renal
insufficiency, and lack of informed consent. For the
registry, exclusion criteria were: participation in the
randomized trial and inability to comply with 30-day
and 6-month follow-up. In addition, for these analy-
ses, patients with a Killip class of IV were excluded.
All patients gave informed consent. The protocol re-
ceived ethics committee approval in all countries.
Randomization and treatment
Figure 1 shows the distribution of patients entered
into the randomized trial and registry. All eligible
patients who were enrolled in the randomized trial
were randomized to receive unfractionated heparin
or enoxaparin, and tirofiban or placebo in a 2 × 2 fac-
torial design. All patients received a minimum initial
dose of 160 mg aspirin, followed by at least 30 days
of 100–325 mg aspirin. Patients enrolled in the reg-
istry were categorized as either ‘received reperfusion
therapy’ or ‘did not receive reperfusion therapy’.
Fig. 1. Overview of the TETAMI study (randomized trial and
registry). STEMI = ST-segment elevation myocardial
infarction.
End points
The primary end point was the combined incidence of
all-cause death, reinfarction, and recurrent angina,
analyzed at 30 days. Secondary end points included
the composite of death and reinfarction at 30 days,
incidence of all-cause death at 30 days, recurrent
angina at 30 days, and invasive cardiac procedures.
Recurrent infarction was diagnosed on the basis of
symptoms, changes in electrocardiographic findings
and serum cardiac markers, using predefined cri-
teria [7,8]. Recurrent angina was defined as (i) a
single episode of angina at rest lasting at least 20
minutes or at least 2 episodes lasting at least 10
minutes within 24 hours, accompanied by new ST-
segment changes, or (ii) angina associated with in-
vasive cardiac procedures or rehospitalization for un-
stable angina. Safety parameters recorded included
the incidence of major hemorrhage, which was de-
fined using Thrombolysis In Myocardial Infarction
(TIMI) criteria [10].
Statistics
The incidence of the triple end point at 30 days
was described for men and women in the follow-
ing groups: registry—received reperfusion therapy,
registry—did not receive reperfusion, and random-
ized trial. A multivariate analysis was performed
to determine predictors of not receiving reperfusion
therapy. Predictors of outcomes (30-day composite
end point or death) were also analyzed. The following
variables were included in the analysis, continuous
variables were analyzed in a categorical manner: age
(<60, 60–75, >75 years), gender, time from symptom
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Fig. 2. Patients receiving reperfusion therapy (thrombolytic therapy or percutaneous coronary intervention), by gender and region.
ROW = rest of the world (Australia, New Zealand, USA, and Israel).
onset to admission (<6 hours, ≥6 hours), systolic
blood pressure (≤100, >100), diastolic blood pres-
sure (≤80, >80), heart rate, Killip class I versus II
or III, and geographic region (South America; Eu-
rope; South Africa; and the rest of the world, which
included Australia, New Zealand, USA, and Israel).
A backward analysis was performed, with a signifi-
cance of p = 0.05 for removal of variables from the
model. Hosmer-Lemeshow statistics for goodness of
fit were calculated. Statistical analyses were per-
formed using the Statistical Analysis System (SAS)
software package version 8.2.
Results
Baseline characteristics
A total of 2741 patients (2034 men and 707 women)
were enrolled in the TETAMI randomized trial and
registry (Fig. 1). Baseline characteristics of the pa-
tients, by treatment status with reperfusion and gen-
der are shown in Table 1. Compared with treated
patients, patients who did not receive reperfusion
tended to be older and to present later after symp-
tom onset. Of the total number of patients included
in both the randomized trial and registry, a trend to-
wards more men than women receiving reperfusion
therapy was observed (47.3 vs. 38.2%). This trend
was observed for all geographic regions studied ex-
cept for South Africa, where there appeared to be no
difference between the number of men and women re-
ceiving reperfusion therapy (Fig. 2). Female patients
tended to be older, have a higher Killip class rat-
ing, and present slightly later from symptom onset
(Table 1).
A trend towards a lower incidence of the 30-day
composite end point of death, reinfarction, and recur-
rent angina was observed for both reperfused com-
pared with non-reperfused patients (10.9 vs. 17.3%),
Fig. 3. Thirty-day composite end point by gender and
reperfusion status.
and for men compared with women (13.3 vs. 17.8%).
Overall, men receiving reperfusion appeared to have
the best prognosis, and women not referred for reper-
fusion had the worst prognosis (Fig. 3). This pattern
was evident in all geographic regions.
Among all of the factors examined, multivari-
ate analysis identified age >75 years, time from
symptom onset to hospital admission, high systolic
blood pressure and region (South Africa) as sig-
nificant independent predictors (p < 0.05) of not
receiving reperfusion therapy (Table 2). The Hosmer-
Lemeshow value for this model was 0.590, with a c-
statistic of 0.896. Significant predictors of the triple
end point (p < 0.05) included not receiving reper-
fusion, age >60 years, and higher Killip class. Geo-
graphic region (Europe) was a predictor of not having
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Table 1. Baseline Characteristics of Patients in the TETAMI Study (Randomized Trial and Registry), by Treatment Status and
Gender
Registry, received Did not receive reperfusion
reperfusion (randomized trial + registry)
(n = 1233) (n = 1508)
Men Women Men Women
Characteristic (n = 963) (n = 270) (n = 1071) (n = 437)
Median age (years) 58 69 61 71
Killip class I 85.6% 75.6% 86.0% 77.6%
Killip class II 12.8% 21.1% 12.7% 18.8%
Killip class III 1.7% 3.3% 1.3% 3.7%
Median time from 2.5 2.7 16.4 16.7
symptom onset to
admission (hours)
Median blood pressure 130/80 137/80 130/80 135/80
(mmHg)
Heart rate, bpm 76 76 74 78
bpm: beats per minute; TETAMI: Treatment with Enoxaparin and Tirofiban in Acute Myocardial Infarction.
Table 2. Predictors of Not Receiving Reperfusion Therapy (N = 2716; Patients with Missing Data Deleted)
Coefficient Odds ratio
95% Wald confidence
Variable Estimate SE p value∗ Estimate interval
Age 60–75 years −0.205 0.127 0.1083 0.815 0.635–1.046
Age >75 years† −0.855 0.179 <0.0001 0.425 0.300–0.604
Systolic blood pressure >100 bpm† −0.564 0.194 0.0035 0.569 0.389–0.831
Time to treatment ≥6 hours† −3.922 0.120 <0.0001 0.020 0.016–0.025
Geographic region
South America −0.058 0.201 0.7732 0.944 0.636–1.399
Europe −0.100 0.184 0.5869 0.905 0.631–1.298
South Africa† −0.778 0.239 0.0011 0.459 0.287–0.734
Female gender Not retained
Killip class Not retained
Heart rate >80 bpm Not retained
∗Wald chi-square.
†Significant, p ≤ 0.05.
bpm: beats per minute; SE: standard error.
Probability modeled: having reperfusion therapy. The Hosmer-Lemeshow value for this model was 0.590, with a c-statistic of 0.896.
a triple end point (Table 3). The Hosmer-Lemeshow
value for this model was 0.436, with a c-statistic
of 0.660. The significant independent predictors of
death at 30 days (p < 0.05) were age >60 years,
higher Killip class, low systolic blood pressure, heart
rate, time from symptom onset to hospital admis-
sion, and the geographic regions South America and
South Africa (Table 4). The Hosmer-Lemeshow value
for this model was 0.131, with a c-statistic of 0.778.
Discussion
The present study, based on prospectively gathered
data on all-comers with STEMI within 24 hours of
symptom onset, demonstrates important differences
in admission characteristics and outcomes between
men and women with STEMI. In general, women
have a higher mortality rate, whether or not they re-
ceive reperfusion therapy, compared with men. These
results parallel those of previous studies that also
show that women with acute myocardial infarction
have a worse prognosis than men [5,11,12], even be-
yond 1 year [13,14].
Similar findings to ours regarding in-hospital mor-
tality were reported in a prospective registry of 9589
European patients with acute coronary syndromes,
although this gender difference was eliminated after
adjusting for age and other confounding factors [12].
Data from the North American National Registry of
Myocardial Infarctions 2 (NRMI 2) showed that, of
the 384 878 patients surviving to reach hospital after
an acute myocardial infarction, age was an important
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Table 3. Predictors of Triple End Point (N = 2716; Patients with Missing Data Deleted)
Coefficient Odds ratio∗
Variable Estimate SE p value‡ Estimate 95% Wald confidence interval
Reperfusion‡ −0.460 0.117 <0.0001 0.631 0.502–0.794
Age 60–75 years‡ 0.352 0.122 0.0039 1.422 1.119–1.806
Age >75 years‡ 0.906 0.139 <0.0001 2.473 1.883–3.247
Killip Class‡ 0.697 0.132 <0.0001 2.008 1.551–2.600
Geographic region
South America −0.039 0.177 0.8270 0.962 0.679–1.362
Europe‡ −0.530 0.167 0.0015 0.589 0.425–0.817
South Africa −0.167 0.217 0.4417 0.846 0.553–1.295
Time to treatment ≥6 hours Not retained
Female gender Not retained
Systolic blood pressure >100 bpm Not retained
Heart rate >80 bpm Not retained
∗Odds ratio adjusted from multivariable analysis.
†Wald Chi-Square.
‡Significant, p ≤ 0.05.
bpm: beats per minute; SE: standard error.
Probability modeled: having a component of the triple endpoint. The Hosmer-Lemeshow value for this model was 0.436, with a c-statistic of 0.660.
Table 4. Predictors of Death at 30 Days (N = 2716; Patients with Missing Data Deleted)
Coefficient Odds ratio∗
Variable Estimate SE p value† Estimate 95% Wald confidence interval
Age 60–75 years‡ 0.821 0.215 0.0001 2.274 1.491–3.468
Age > 75 years‡ 1.761 0.229 <0.0001 5.819 3,715–9.114
Killip class‡ 1.014 0.180 <0.0001 2.757 1.936–3.925
Systolic blood pressure >100 bpm‡ −0.686 0.239 0.004 0.504 0.316–0.803
Time to treatment ≥6 hours‡ 0.545 0.176 0.0020 1.725 1.221–2.438
Geographic region
South America‡ 0.690 0.319 0.0307 1.994 1.066–3.728
Europe 0.314 0.305 0.3040 1.368 0.752–2.489
South Africa‡ 1.039 0.352 0.0031 2.828 1.419–5.636
Heart rate >80 bpm‡ 0.620 0.171 0.0003 1.858 1.328–2.599
Female gender Not retained
Reperfusion Not retained
∗Odds ratio adjusted from multivariable analysis.
†Wald chi-square.
‡Significant, p ≤ 0.05.
bpm: beats per minute; SE: standard error.
Probability modeled: death. The Hosmer-Lemeshow value for this model was 0.131, with a c-statistic of 0.778.
potential factor for excess mortality in women [5].
However in that study, younger rather than older
women had higher rates of mortality after a STEMI
than men of the same age. These findings have been
confirmed in a more recent study of 8277 patients by
the same author [14]. In the current analysis, multi-
variate analysis also revealed that although female
patients had worse outcomes, female gender was not
a predictor of either death or the triple end point. Age,
not receiving reperfusion therapy, and Killip class
were predictive of 30-day all-cause death, myocar-
dial infarction, or recurrent angina (composite end
point). These results are similar to those obtained by
the GUSTO study group, where in a group of 41 021
patients receiving lytic therapy, female gender was
predictive of worse outcome, but advanced age was
identified as the strongest predictor of adverse out-
come [15]. However, female gender was described in
this study as being a borderline predictor of adverse
outcome.
Evidence exists to suggest that this increased mor-
tality rate in women may be a result of underuti-
lization of reperfusion therapy [16]. In the current
study, women were less likely to receive reperfusion
therapy than men, and non-use of reperfusion ther-
apy was predictive of the triple end point. However
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in this study, the strongest predictors of not receiv-
ing reperfusion therapy were advanced age, delayed
presentation, high systolic blood pressure and geo-
graphic region (South Africa). Previous studies have
shown that women are less likely to be considered for
reperfusion therapy than men, in some cases even af-
ter adjusting for important clinical differences [17–
19]. Despite the higher mortality rates in women,
fewer women may receive major diagnostic and ther-
apeutic procedures than men [20–22], even though
women treated with early aggressive revasculariza-
tion procedures may have a better long-term outcome
than that of men [23].
The underutilization of thrombolytic therapy in
women may be partly a result of a longer time from
symptom onset to hospital arrival compared with
men [5,18,19,24]. Possible reasons for the longer de-
lay may be the age at which women experience a first
myocardial infarction, concomitant chronic diseases,
atypical presentation of cardiac symptoms, and a re-
duced perception of risk of myocardial infarction by
women themselves and healthcare providers. These
factors are compounded by atypical and more tran-
sient symptoms at presentation [24].
In our study, we also found that geographic re-
gion appeared to be a predictor of adverse outcome.
This should be interpreted with caution, as the num-
ber of patients per region was not balanced, and the
type of center differed from region to region. South
Africa was a predictor of both not receiving reperfu-
sion therapy and death at 30 days, which are prob-
ably interrelated, whereas the finding that South
America was linked to worse outcome could well be
due to other confounding baseline factors that are
not controlled for in this analysis. A recent report
from the TIMI 11b trial conducted in non-ST-segment
elevation acute coronary syndromes, showed that
when a larger sample size was compared among re-
gions, such geographic regional differences were not
apparent [25].
Conclusions
The findings from the present study of more than
2500 consecutive patients with STEMI prospectively
followed from the TETAMI trial and registry show
important gender differences in outcomes and treat-
ment of STEMI. Female patients tend to have worse
outcomes and receive reperfusion therapy less of-
ten than male patients. After multivariate analy-
sis, age and delayed presentation, but not gender,
were significant predictors of both non-reperfusion
and of adverse outcomes. Non-reperfusion was also
an independent predictor of the triple end point. De-
spite the increase in gender-directed studies in recent
years, major gaps remain in our understanding of
differences in presentation, prognosis, and response
to treatment between men and women. Increased
awareness of these differences is needed, particularly
to reduce the delay in presentation of women with
STEMI and to remove any treatment bias that may
exist; i.e. reperfusing more eligible female STEMI pa-
tients. Further prospective studies are required to
determine optimal therapies for patients ineligible
for reperfusion.
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